4.7 Article

Structural Insights into the Novel Diadenosine 5′,5′′′-P1,P4-Tetraphosphate Phosphorylase from Mycobacterium tuberculosis H37Rv

Journal

JOURNAL OF MOLECULAR BIOLOGY
Volume 410, Issue 1, Pages 93-104

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2011.04.059

Keywords

X-ray crystallography; mycobacteria; nucleotide; mutation; kinetics

Funding

  1. Ministry of Health, Labor, and Welfare of Japan [H22-Shinkou-Ippan-007]
  2. Ministry of Education, Culture, Sports, Science and Technology of Japan [20780066]
  3. Grants-in-Aid for Scientific Research [20780066] Funding Source: KAKEN

Ask authors/readers for more resources

Rv2613c is a diadenosine 5',5'''-P-1,P-4-tetraphosphate (Ap(4)A) phosphorylase from Mycobacterium tuberculosis H37Rv. Sequence analysis suggests that Rv2613c belongs to the histidine triad (HIT) motif superfamily, which includes HIT family diadenosine polyphosphate (Ap(n)A) hydrolases and Ap(4)A phosphorylases. However, the amino acid sequence of Rv2613c is more similar to that of HIT family Ap(n)A hydrolases than to that of typical Ap(4)A phosphorylases. Here, we report the crystal structure of Ry2613c, which is the first structure of a protein with Ap(n)A phosphorylase activity, and characterized the structural basis of its catalytic activity. Our results showed that the structure of Rv2613c is similar to those of other HIT superfamily proteins. However, Asn139, Gly146, and Ser147 in the active site of Ry2613c replace the corresponding Gln, Gln, and Thr residues that are normally found in HIT family Ap(n)A hydrolases. Furthermore, analyses of Rv2613c mutants revealed that Asn139, Gly146, and Ser147 are important active-site residues and that Asn139 has a critical role in catalysis. The position of Gly146 might influence the phosphorylase activity. In addition, the tetrameric structure of Rv2613c and the presence of Trp160 might be essential for the formation of the Ap(4)A binding site. These structural insights into Rv2613c may facilitate the development of novel structure-based inhibitors for treating tuberculosis. (C) 2011 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available